Kornimate/medical-research-clean huggingface dataset:
cleaning of the nose after sinus surgery: necessary or only bothersome?

Conditions: Acute Recurrent Rhinosinusitis

Summary: the goal of this study is to increase knowledge about how to treat patients after sinus surgery.

many surgeons consider the postoperative treatment after sinus surgery as important for the outcome as the surgery itself. however, postoperative treatment regimes differ considerably between surgeons. they include non-intervention, frequent in-office endoscopic debridement, stenting of the middle meatus, saline douching or irrigation of the nose, or combinations of these measures in various ways. the lack of consensus is unfortunate. it indicates a lack of knowledge about how to treat these patients optimally after surgery. this is partly due to a lack of internationally acknowledged randomised, comparative, prospective studies on the effects of the various postoperative measures and their interactions. accordingly, some patients may receive a too intensive postoperative follow up, with unnecessary frequent visits with the doctor, unnecessary bleeding and inconvenience from unnecessary debridement/cleaning of the nose, and increased costs due to unnecessary medication. conversely, there may be patients that receive too little attention in the postoperative period, and thus may have a suboptimal result of the operation. frequent cleaning/debridement of the nose after sinus surgery is believed to improve the outcome of functional endoscopic sinus surgery (fess). however, the scientific data on its effects are limited. the purpose of this study was to evaluate the effects of cleaning/ debridement of the middle meatus 5-7 days and 12-14 days after sinus surgery in a randomized, partly blinded, controlled clinical trial.

Eligibility criteria:
inclusion criteria: * inclusion criteria are acute recurrent rhinosinusitis and chronic rhinosinusitis. the investigators used the classification of rhinosinusitis proposed by lanza and kennedy. exclusion criteria: * previous fess * systemic disease with affection of the nose (wegener's granulomatosis, cystic fibrosis, kartagener's syndrome, sarcoid) * primary ciliary dyskinesia * pregnancy * septoplasty in the same surgery * ongoing treatment for cancer

Keywords: sinus surgery endoscopic postoperative care debridement randomized acute recurrent rhinosinusitis chronic rhinosinusitis nasal polyps chronic rhinosinusitis with nasal polyps chronic rhinosinusitis without nasal polyps
anodal and cathodal transcranial direct current stimulation in stroke recovery

Conditions: Stroke

Summary: the purpose of this study will to compare the long-term effect of anodal versus cathodal transcranial direct current stimulation (tdcs) on motor recovery in subacute stroke patients. forty patients with subacute ischemic stroke will randomly assigned to one of three groups: anodal, cathodal and sham. each group will receive tdcs at an intensity of 2ma for 25 minutes daily for 6 consecutive days over the affected (anodal, sham) or unaffected (cathodal) motor cortex. patients will be assessed with national institutes of health stroke scale (nihss), the barthel index (bi) and the medical research council (mrc) muscle strength scale at baseline, after end of the 6th tdcs session, and then 1, 2 and 3 months later. motor cortical excitability will be measured at baseline and after the 6th session in both hemispheres.


Eligibility criteria:
inclusion criteria: * acute hemiparesis with single thromboembolic non-hemorrhagic infarction documented by magnetic resonance imaging (mri) * accept to participate in the study exclusion criteria: * extensive infarction (taking all territories of middle cerebral artery) * severe flaccid hemiplegia * head injury * any other neurological disease other than stroke * previous administration of tranquilizer * patients who are unable to give informed consent because of severe aphasia, or cognitive deficit. * patients with no motor evoked response recorded from first dorsal interosseus (fdi) muscle of the affected hand

Keywords: ischemic stroke direct current stimulation motor threshold national institutes of health stroke scale barthel index scale measurement of motor power improvement
study of scaling disorders and other inherited skin diseases

Conditions: Genetic Skin Disease; Keratosis Follicularis; Lamellar Ichthyosis

Summary: the purpose of this study is to identify the genes responsible for certain scaling disorders and other inherited skin diseases and to learn about the medical problems they cause. in some cases, these may include problems affecting organs other than the skin, such as the eyes, teeth and bones. patients with inherited skin disorders, including darier's disease (keratosis follicularis), lamellar ichthyosis, epidermolysis bullosa, cystic acne, and others, and their relatives may be eligible for this study. patients will have a medical history, physical examination with particular emphasis on the skin, and routine blood tests. additional procedures for patients and unaffected relatives may include: 1. blood sample collection 2. dental exam with x-ray of the jaw 3. eye examination 4. x-rays of the skull, ribs, chest, hands, feet, spine, arms, or legs 5. bone density scan 6. photographs of the skin 7. skin biopsies (removal of a small tissue sample under local anesthetic) 8. buccal sample (gentle brushing inside the cheek to collect a cell sample) for gene studies patients who request the results of their gene testing will be provided this information.

we propose to investigate the genetics of the scaling disorders and other genodermatoses which are believed to behave in a mendelian manner. families for study will be ascertained through articles in the ichthyosis focus, (the newsletter of the foundation for ichthyosis and related skin types), physician referrals, and patient self-referrals. efforts will be made to further characterize the clinical findings in both affected persons and unaffected gene carriers. using candidate genes, especially those known to be involved in structural abnormalities of skin, we will attempt to map and isolate major genes contributing to expression of the disease phenotype. failing this direct approach, a random search of the genome (so-called, "reverse genetics") will be utilized. in addition, normal and diseased skin will be used in cell culture and animal experiments (under a separate protocol) to test new therapeutic modalities.

Eligibility criteria:
no steroid sulfatase deficiency.

Keywords: dna markers family studies gene mapping ichthyosis keratin linkage analysis scaling disorders skin
ictal spect with intra-arterial injection

Conditions: Epilepsy

Summary: ictal spect with intravenous injection in a cubital vein of a perfusion tracer is an established technique to localize the ictal onset zone during presurgical evaluation of refractory focal epilepsy. when seizures last less than 10 seconds, localizing information is often not obtained. since it takes around 30 seconds before the tracer reaches the brain after intravenous injection, ictal hyperperfusion most likely has already switched to postictal hypoperfusion. in this study, we plan to inject the perfusion tracer in the aorta proximal to the cerebral arteries, which will allow a true ictal injection in patients with seizures of short duration.

in this study, the investigators will select one patient with refractory focal epilepsy with frequent seizures of short duration, which can not be localized with early ictal spect with intravenous injection in a cubital vein. an arterial catheter will be inserted. the right groin will be disinfected using an alcoholic disinfectant and locally anaesthetized. the artery in the groin, the femoral artery, will be punctured. a catheter is inserted in the artery and slided towards the heart. to determine the correct position of the catheter proximal to the cerebral arteries, a contrast agent will be injected, and at the same time radiographs will be taken. the catheter will be attached and taped in the groin. the patient will be monitored with video-eeg recording. during an epileptic seizure, the perfusion tracer 99m-technetium ethyl cysteinate dimer (99mtc- ecd) dissolved in 30 cc normal saline will be injected with a pressure injector over 2 seconds. after injection, the catheter will be removed and the ictal spect scan will be performed. subtracted ictal spect images co-registered with mri (siscom) will be obtained. the investigators plan to do this study in one patient in order to assess whether this procedure is logistically possible and to determine whether subtraction images of ictal spect with intra-arterial injection minus interictal spect with intravenous injection allows localization of the ictal onset zone.

Eligibility criteria:
inclusion criteria: * refractory unifocal epilepsy * early ictal spect with intravenous injection did not localize the ictal onset zone * several seizure per day, or clusters of several seizures per day * seizures are of short duration (i.e. less than 10-15 seconds) * patient asks for epilepsy surgery exclusion criteria: * renal failure * allergy to contrast agents * fever * anemia * usage of anticoagulants * pregnancy

Keywords: ictal spect
efficacy and safety of long-term oral staphylococcus albicans tablets in patients with bronchiectasis

Conditions: Bronchiectasis

Summary: the main purpose of this study is to investigate whether long-term oral administration of staphylococcus albicans tablets can significantly reduce the number of acute exacerbations in patients with bronchiectasis. secondary objective is to explore whether long-term oral administration of staphylococcus albicans tablets can reduce the risk of hospitalization in patients with bronchiectasis and whether it can improve the quality of life of patients. other purpose is to explore the regulatory effect of long-term oral administration of staphylococcus albicans tablets on the immune function of patients with bronchiectasis.

bronchiectasis is a chronic airway purulent disease. the four factors of "vicious circle" play an important role in the occurrence, development and prognosis of bronchiectasis. attempts to breaks the vicious circle may be beneficial to reduce the acute exacerbation of bronchiectasis. the main ingredients of staphylococcus albicans tablets are the inactivated cells of staphylococcus albus, catarella catarrhalis and bacillus subtilis. it may be beneficial to improve the non-specific immunity of patients and the specific immune function of respiratory mucosa, and reduce airway mucus secretion and secretion retention. there is not yet sufficient clinical evidence to support the immune function regulation and related efficacy of patients. therefore, the efficacy of long-term oral administration of staphylococcus albicans tablets in patients with bronchiectasis needs to be further confirmed by clinical studies.

Eligibility criteria:
inclusion criteria: * patients with bronchiectasis diagnosed by clinical manifestations and chest hrct according to the diagnostic criteria for bronchiectasis; * patients with idiopathic or post-infectious bronchiectasis; * 18years old; * patients should have at least 2 acute exacerbations within 1 year before enrollment; * patients in either acute exacerbation or stable period can be included. exclusion criteria: * cystic fibrosis; * immunodeficiency, allergic bronchopulmonary aspergillosis, etc.; * traction bronchiectasis caused by severe emphysema or advanced pulmonary fibrosis; * still smoking; * complicated with asthma or chronic obstructive disease lung; * patients with severe cardiovascular disease, severe neurological disease, or severe liver or kidney damage; * malignant tumors; * allergy to staphylococcus albicans tablets; * patients with a history of gastric ulcer or intestinal malabsorption; * pregnant or lactating women; * patients with poor compliance; * previous (within 6 months before the start of the study) or concurrently taking immunostimulating drugs (including thymosin, interferon, transfer factor, bcg, pneumonia vaccine and any kind of bacteria extracts, such as biostim, except for influenza vaccine) or immunosuppressants; * patients who are participating in or have participated in interventional clinical trials within 3 months.
a multi-centre study comparing the polyp detection rate of two different types of bowel preparation: a 2-litre solution (moviprep®) versus a hyperosmotic and stimulant combined low volume bowel preparation (sodium picosulfate and magnesium citrate)

Conditions: Colorectal Cancer

Summary: to compare the polyp and adenoma detection rate of moviprep versus an oral sodium picosulfate/magnesium citrate solution.


Eligibility criteria:
inclusion criteria: * patient's written informed consent must be obtained prior to inclusion. * male or female outpatients or inpatients aged 40 to 80 years with an indication for complete colonoscopy. * willing to undergo a colonoscopy for diagnostic or surveillance purposes * patients with a known personal of familial risk of colon neoplasia, willing to undergo a screening colonoscopy * willing, able and competent to complete the entire procedure and to comply with study instructions. * females of childbearing potential must employ an adequate method of contraception. exclusion criteria: * history of gastric emptying disorders. * history of ileus, toxic megacolon, gastrointestinal obstruction and colonic perforation. * history of phenylketonuria. * known glucose-6-phosphate dehydrogenase deficiency. * known hypersensitivity to macrogol 3350, sodium sulphate or ascorbic acid/sodium ascorbate. * history of colonic resection. * requirement for permanent medication and associated stable serum concentrations (e.g. neuroleptic drugs). * presence of congestive heart failure (nyha iii + iv). * acute life-threatening cardiovascular disease. * documented history of severe renal insufficiency (creatinine clearance \<30 ml/min). * other contraindication described in the summary of product characteristics (smpc) of either preparation. * patient has a condition, clinically significant laboratory results, or is in a situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly. * application of any unlicensed medication within the previous 3 months or participation in any other research study in the last 3 months. * females who are pregnant, nursing or planning a pregnancy. * patients who, in the opinion of the investigator, may not be compliant with the study requirements. * previous participation in this clinical study.
evaluation of mental flexibility through language tests in adolescents with frontal brain damage and in healthy children in ages 8-17

Conditions: Persons With Frontal Lobe Damage With no Specific Language Disorder

Summary: this study aims to shed light on the theoretical concept of mental flexibility and its manifestation in adolescents following frontal lobe damage, and to develop a test battery for young hebrew speakers.


Eligibility criteria:
inclusion criteria: * frontal lobe damage * at least one year after injury * native hebrew speaker exclusion criteria: * specific language disorder * premorbid learning disability
does class of dietary fat affect insulin resistance?

Conditions: Insulin Resistance

Summary: it has been shown that intravenous fatty acids given to normal volunteers in the form of heparin and lipid emulsions will cause insulin resistance in a matter of a few hours. it is not known if this same phenomenon can be demonstrated with oral fat. the investigators are specifically interested in whether or not there are differences in the induction of insulin resistance between the 3 main classes of fatty acids (saturated, monounsaturated and polyunsaturated). the investigators also plan to evaluate endothelial dysfunction and blood pressure; both of which frequently accompany insulin resistance.

type 2 diabetes and cardiovascular disease are closely linked. a common abnormality in both conditions is insulin resistance. the primary cause of insulin resistance in not known. a significant question is what dietary components contribute to the development of insulin resistance. based on epidemiologic data, it seems that the type of dietary fat is a significant contributor to the development of insulin resistance. however, some researchers argue that the main determinant is total amount of fat, not the composition. this study is intended to determine if the main types of fat (saturated, monounsaturated and polyunsaturated) ingested over a short time can cause insulin resistance in lean, healthy people. it has been demonstrated that 6 hours of intravenous fat infused into lean, healthy subjects can result in insulin resistance, as well as blood pressure elevation and endothelial dysfunction. whether this is so with oral fat is not known. the question is important because there is debate about whether the type of fat is as important as the quantity of fat in a person's daily diet. settling this debate will enhance the ability of health care personnel to determine the optimal dietary recommendations. this study will make use of a high fat diet consisting of vegetable oils high in the 3 main fatty acids in plasma (palmitate, oleate and linoleate). because large fat loads can cause intestinal discomfort, a feeding tube will be used to bypass the stomach. the 3 oils will be assigned randomly following a base line study with saline 2 weeks prior to the intervention. our primary endpoint is insulin resistance, which will be measured by a euglycemic, hyperinsulinemic clamp. secondary measures will include changes in blood pressure and in vascular reactivity as measured by ultrasound after brief occlusion of a forearm vessel. the changes will be compared to baseline and to the other 2 groups.

Eligibility criteria:
inclusion criteria: * lean,healthy adults 18 - 40 * no chronic medications (birth control pills allowed) * weight stable * normal fasting labs performed at screening * body mass index ≤ 25 kg/m\^2 . exclusion criteria: * insulin dependent diabetes * thyroid disease * history of diabetes or heart disease * history of type 2 diabetes in parent or sibling

Keywords: insulin resistance endothelial dysfunction saturated fat monounsaturated fat polyunsaturated fat
trial to assess the efficacy and safety of leo 152020 in adult patients with cholinergic urticaria

Conditions: Cholinergic Urticaria

Summary: phase 2a trial to assess the efficacy and safety of leo 152020 in adult patients with cholinergic urticaria

this is a phase 2a, randomised, double-blind, placebo-controlled, cross-over trial conducted in germany at 3-6 sites. subjects will be randomised to one of two treatment sequences (a and b). each treatment period will last 7 days with a wash-out period of 7 days between treatments. half of the subjects will start with treatment a followed by treatment b while the other half will start with treatment b followed by treatment a. a safety follow-up visit will be performed 3 days after last dose of the tested medication. the main assessment is an urticaria activity score. after a pulse-controlled ergometry (pce) provocation test subjects will be rated on their number of wheals and their itch severity, resulting in a sum score ranging from 0 to 6 points.

Eligibility criteria:
main inclusion criteria: * subject with a history of cholinergic urticaria diagnosis for ≥ 6 months * subject has active and uncontrolled cholinergic urticaria disease at the time of screening and randomisation, as defined by the following: 1. urticaria control test \< 12 at screening 2. urticaria activity score post-provocation ≥ 3 * recent history (within 6 months of screening) with documented inadequate response to standard dose as to marketing authorization of h1 antihistamines. main exclusion criteria: * other clearly dominating forms\* of urticaria as aetiology for wheal and flare type reactions \*these diseases are allowed as comorbidities, if cholinergic urticaria is the dominating form of chronic urticaria, * systemic immunosuppressive medications within 4 weeks prior to screening, * systemic drugs (e.g. oral drug) with antihistamine properties including h1 antihistamines and some antidepressants (e.g. tricyclic antidepressants) and h2 antihistamines 1 week prior to randomisation and throughout the trial. however, topical antihistamines in the form of nasal spray and eyedrops are allowed in the standard prescribed dose.
significance of serum tenascin c in patients with acute aortic disease

Conditions: Aortic Dissection

Summary: this study aims to investigate serum tenascin c levels in patients with acute symptoms relating to a known or newly diagnosed aortic aneurysm in emergency department and reveals the possible role of tenascin c in the development of the disease.

patients with acute and chronic aortic disease /survivors and non-survivors were compared. further subgroup analysis on the characteristics of the aneurysm and patients were performed. the aneurysms (ruptured and dissected) were divided according to the style of the stanford classification,according to the location of the pathology in aneurysms of the ascending thoracic aorta .the descending thoracic aorta, or the abdominal aorta.the subgroup were divided according to the extent of propagation of the disease (rupture,covered rupture, acute dissection, chronic dissection and ectasia). rupture was defined by direct visualisation of the discontinuity of the aortic wall by computed tomography, sonography, intraoperative findings or at autopsy with detection of blood in the pleural, pericardial or abdominal cavity. covert rupture was defined as an intramural haematoma without detection of free blood in the body cavities. acute dissection was defined when blood separating the layers of the aortic media was newly diagnosed. chronic dissection was defined as the absence of any visible propagation of a known dissection compared to preexisting examinations. ectatic aneurysm was defined as a permanent localised dilatation of the aorta with a diameter of at least 50% greater than normal. documentation of the surgical interventions and autopsy reports was used to confirm the diagnosis. in all patients the investigators collected the history, age of the patients, duration of pain, blood pressure at admission and laboratory parameters (haematocrit, creatinine) and tenascin c serum levels after admission to our emergency department immediately. the patients were followed up until hospital discharge and the outcome (survived/died) was recorded.

Eligibility criteria:
inclusion criteria: * adults * sudden severe thoracic or abdominal pain exclusion criteria: * lesser than 18 years * pregnant women * trauma * tumour

Keywords: aortic dissection biomarkers diagnosis
maternal microcirculation & sdf imaging

Conditions: Pregnancy

Summary: this is a study of pregnant women undergoing a cesarean delivery. it will compare their microcirculation before and after the anesthetic. microcirculation means blood flow to the extremely small blood vessels in the body. it will also look at the differences in microcirculation of participants who receive an infusion of phenylephrine compared to participants who don't. the investigators hypothesize that spinal anesthesia will reduce the vascular density and proportion of perfused vessels.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i-ii (asa i - healthy, asa ii - mild and controlled systemic disease) * singleton pregnancies * 36-42 weeks gestation * non-labouring * scheduled cesarean delivery * english speaking * age 18-45 years exclusion criteria: * cardiovascular disease * hypertensive disease of pregnancy (i.e. mild \& severe preeclampsia) * allergy to phenylephrine, or any other standardized medication * obesity (bmi \> 35 kg/m2) * diabetes mellitus type 1 * smoker * coffee/caffeine intake within 6 hours of sdf measurement

Keywords: microcirculation sidestream dark field (sdf) imaging spinal anesthesia phenylephrine